m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in epithelial ovarian cancer
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Cisplatin (DDP)-based chemotherapy is a common chemotherapeutic regimen for the treatment of advanced epithelial ovarian cancer (EOC). However, most patients rapidly develop chemoresistance. N6-methyladenosine (m6A) is a pervasive RNA modification, and its specific role and potential mechanism in the regulation of chemosensitivity in EOC remain unclear.
METHODS: The expression of RIPK4 and its clinicopathological impact were evaluated in EOC cohorts. The biological effects of RIPK4 were investigated using in vitro and in vivo models. RNA m6A quantification was used to measure total m6A levels in epithelial ovarian cancer cells. Luciferase reporter, MeRIP-qPCR, RIP-qPCR and actinomycin-D assays were used to investigate RNA/RNA interactions and m6A modification of RIPK4 mRNA.
RESULTS: We demonstrated that RIPK4, an upregulated mRNA in EOC, acts as an oncogene in EOC cells by promoting tumor cell proliferation and DDP resistance at the clinical, database, cellular, and animal model levels. Mechanistically, METTL3 facilitates m6A modification, and YTHDF1 recognizes the specific m6A-modified site to prevent RIPK4 RNA degradation and upregulate RIPK4 expression. This induces NF-κB activation, resulting in tumor growth and DDP resistance in vitro and in vivo.
CONCLUSIONS: Collectively, the present findings reveal a novel mechanism underlying the induction of DDP resistance by m6A-modified RIPK4, that may contribute to overcoming chemoresistance in EOC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:180 |
|---|---|
| Enthalten in: |
Gynecologic oncology - 180(2024) vom: 21. Jan., Seite 99-110 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yin, Xinming [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 23.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ygyno.2023.11.034 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365769037 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365769037 | ||
| 003 | DE-627 | ||
| 005 | 20240229143935.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ygyno.2023.11.034 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM365769037 | ||
| 035 | |a (NLM)38086167 | ||
| 035 | |a (PII)S0090-8258(23)01588-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yin, Xinming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in epithelial ovarian cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Cisplatin (DDP)-based chemotherapy is a common chemotherapeutic regimen for the treatment of advanced epithelial ovarian cancer (EOC). However, most patients rapidly develop chemoresistance. N6-methyladenosine (m6A) is a pervasive RNA modification, and its specific role and potential mechanism in the regulation of chemosensitivity in EOC remain unclear | ||
| 520 | |a METHODS: The expression of RIPK4 and its clinicopathological impact were evaluated in EOC cohorts. The biological effects of RIPK4 were investigated using in vitro and in vivo models. RNA m6A quantification was used to measure total m6A levels in epithelial ovarian cancer cells. Luciferase reporter, MeRIP-qPCR, RIP-qPCR and actinomycin-D assays were used to investigate RNA/RNA interactions and m6A modification of RIPK4 mRNA | ||
| 520 | |a RESULTS: We demonstrated that RIPK4, an upregulated mRNA in EOC, acts as an oncogene in EOC cells by promoting tumor cell proliferation and DDP resistance at the clinical, database, cellular, and animal model levels. Mechanistically, METTL3 facilitates m6A modification, and YTHDF1 recognizes the specific m6A-modified site to prevent RIPK4 RNA degradation and upregulate RIPK4 expression. This induces NF-κB activation, resulting in tumor growth and DDP resistance in vitro and in vivo | ||
| 520 | |a CONCLUSIONS: Collectively, the present findings reveal a novel mechanism underlying the induction of DDP resistance by m6A-modified RIPK4, that may contribute to overcoming chemoresistance in EOC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cisplatin resistance | |
| 650 | 4 | |a Epithelial ovarian cancer | |
| 650 | 4 | |a N6-methyladenosine(m6A) | |
| 650 | 4 | |a RIPK4 | |
| 650 | 4 | |a YTDHF1 | |
| 650 | 7 | |a 6-methyladenine |2 NLM | |
| 650 | 7 | |a W7IBY2BGAX |2 NLM | |
| 650 | 7 | |a Adenine |2 NLM | |
| 650 | 7 | |a JAC85A2161 |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a Methyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.1.1.- |2 NLM | |
| 650 | 7 | |a METTL3 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.1.1.62 |2 NLM | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a RIPK4 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 700 | 1 | |a Zhao, Shijie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Mengxue |e verfasserin |4 aut | |
| 700 | 1 | |a Xing, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jiamin |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Wujiang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yajiao |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Minjun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wenxin |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Junyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xiaolan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gynecologic oncology |d 1972 |g 180(2024) vom: 21. Jan., Seite 99-110 |w (DE-627)NLM000614610 |x 1095-6859 |7 nnns |
| 773 | 1 | 8 | |g volume:180 |g year:2024 |g day:21 |g month:01 |g pages:99-110 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ygyno.2023.11.034 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 180 |j 2024 |b 21 |c 01 |h 99-110 | ||